Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Coya Therapeutics (COYA) EBITDA Margin (2023 - 2025)

Coya Therapeutics' EBITDA Margin history spans 3 years, with the latest figure at 68.07% for Q3 2025.

  • For Q3 2025, EBITDA Margin changed N/A year-over-year to 68.07%; the TTM value through Sep 2025 reached 516.02%, down 39747.0%, while the annual FY2024 figure was 484.58%, 35336.0% down from the prior year.
  • EBITDA Margin for Q3 2025 was 68.07% at Coya Therapeutics, up from 3916.29% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 30.36% in Q4 2023 and bottomed at 208681.1% in Q4 2024.
  • The 3-year median for EBITDA Margin is 2974.24% (2025), against an average of 31431.58%.
  • The largest annual shift saw EBITDA Margin plummeted -20871145bps in 2024 before it soared 134321bps in 2025.
  • A 3-year view of EBITDA Margin shows it stood at 30.36% in 2023, then plummeted by -687559bps to 208681.1% in 2024, then surged by 100bps to 68.07% in 2025.
  • Per Business Quant, the three most recent readings for COYA's EBITDA Margin are 68.07% (Q3 2025), 3916.29% (Q2 2025), and 2974.24% (Q1 2025).